We have examined the effect of activated neutrophils on the release of prostacyclin (PGI2) from cultured endothelial cells by radioimmunoassay and thin layer chromatography of its stable metabolite, 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha). Phorbol myristate acetate-activated neutrophils induced a time-and dose-dependent release of 6-keto-PGF1 alpha from human and bovine endothelial cell monolayers, whereas phorbol myristate acetate alone and neutrophils alone did not. Pretreatment of the endothelial cells with aspirin prevented neutrophil-mediated 6-keto-PGF1 alpha release, indicating that it did not depend upon neutrophil-generated endoperoxides. Phorbol myristate acetate-activated neutrophils from a patient with chronic granulomatous disease failed to induce endothelial 6-keto-PGF1 alpha release. Addition of catalase but not of superoxide dismutase significantly reduced human and bovine endothelial 6-keto-PGF1 alpha release by phorbol myristate acetate-activated neutrophils. Catalase-inhibitable endothelial 6-keto-PGF1 alpha release was also observed after the addition of the hydrogen peroxide-generating system, glucose-glucose oxidase, to bovine and human endothelial cell monolayers. Bovine endothelial 6-keto-PGF1 alpha release induced by exogenously generated hydrogen peroxide was attenuated by the phospholipase inhibitor mepacrine, suggesting that hydrogen peroxide may act by triggering endothelial membrane phospholipase activation. The release of 6-keto-PGF1 alpha by enzymatically or neutrophil-generated hydrogen peroxide was not associated with endothelial cell lysis as assessed by 51Cr release. We conclude that exogenously generated hydrogen peroxide or a hydrogen peroxide-derived product mediates rapid nonlytic release of PGI2 Abstract. We have examined the effect of activated neutrophils on the release of prostacyclin (PGI2) from cultured endothelial cells by radioimmunoassay and thin layer chromatography of its stable metabolite, 6-keto-prostaglandin Fla (6-keto-PGFI,a). Phorbol myristate acetate-activated neutrophils induced a time-and dose-dependent release of 6-keto-PGFIa from human and bovine endothelial cell monolayers, whereas phorbol myristate acetate alone and neutrophils alone did not. Pretreatment of the endothelial cells with aspirin prevented neutrophil-mediated 6-keto-PGFia release, indicating that it did not depend upon neutrophil-generated endoperoxides. Phorbol myristate acetate-activated neutrophils from a patient with chronic granulomatous disease failed to induce endothelial 6-keto-PGFI,a release. Addition of catalase but not ofsuperoxide dismutase significantly reduced human and bovine endothelial 6-keto-PGFI,a release by phorbol myristate acetate-activated neutrophils. Catalaseinhibitable endothelial 6-keto-PGFIa release was also observed after the addition of the hydrogen peroxide-generating system, glucose-glucose oxidase, to bovine and human endothelial cell monolayers. Bovine endothelial 6-keto-PGFI,a release induced by exogenously generated hydrogen peroxide was attenuated by the phospholipase inhibitor mepacrine, suggesting that hydrogen peroxide may act by triggering endothelial membrane phospholipase activation. The release of 6-keto-PGFI,, by enzymatically or neutrophil-generated hydrogen peroxide was not associated with endothelial cell lysis as assessed by 5'Cr release. We conclude that exogenously generated Address reprint requests to Dr. Harlan,
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Introduction
Since augmented neutrophil adherence to vascular endothelium is an early response to inflammation (1) , neutrophils have been implicated in the pathogenesis of the altered vascular permeability associated with acute inflammation (2) . The observation that neutrophil depletion attenuates permeability edema formation in several experimental models supports this hypothesis (3) (4) (5) . Activated neutrophils have been shown to produce endothelial injury in vitro through the generation of toxic oxygen products (6, 7) and the release of granule proteases (8) . Since prostacyclin (PGI2)1 has been demonstrated to have proinflammatory effects and to enhance edema formation (2, 9-16), we have examined the effect ofactivated neutrophils on endothelial PGI2 release by the use of purified human peripheral blood neutrophils, cultured bovine and human endothelial cells (ECs), and radioimmunoassay (RIA) and thin-layer chromatography (TLC) of 6-keto-prostaglandin Fl, (6-keto-PGF,a), the stable breakdown product of PGI2.
Methods
ECs. Bovine aortic and pulmonary artery and human umbilical vein ECs were prepared by collagenase treatment of vessels as previously described (17, 18) The supernatant medium was acidified to pH 3.5 with glacial acetic acid and extracted twice with five times volume of ethyl acetate/cyclohexane (1:1). The organic layer was evaporated to dryness with nitrogen.
Unlabeled 6-keto-PGFIa and PGE2 (Sigma Chemical Co.) were added before extraction to localize these prostaglandins during chromatography. A small aliquot was also removed before and after extraction to correct for recovery. The dried residue was resuspended in 100 Ml ofethyl acetate and applied to a 20 X 20 cm silica gel 60 TLC plate (Merck and Co., Darmstadt, Germany). The plates were developed twice in a watersaturated mixture of ethyl acetate/glacial acetic acid/isooctane (I 10:20:50), and dried in air, and the spots were located with iodine vapor. Areas corresponding to 6-keto-PGFI., PGE2, and arachidonic acid were then removed by scraping, extracted with chloroform/methanol (9:1), and dried under nitrogen, and scintillate was added for counting. Reagents. Acetylsalicylic acid, A23187, phorbol myristate acetate (PMA), soybean trypsin inhibitor (SBTI), mepacrine (quinacrine dihydrochloride), fatty acid-free albumin, catalase (bovine liver, 11,800 U/mg), superoxide dismutase (SOD) (2,700 U/mg), and glucose oxidase (grade VII) were obtained from Sigma Chemical Co. Sodium arachidonate was obtained from Bio/Data Corp. (Horsham, PA).
Results
Neutrophil-mediated bovine endothelial 6-keto-PGF,a release.
Incubation of bovine EC monolayers with PMA alone or neutrophils alone did not induce significant release of 6-keto-PGFIa.
When neutrophils were activated by PMA, however, a marked increase in 6-keto-PGFI,a release was noted. Because baseline (medium alone) and stimulated (arachidonic acid) release of 6-keto-PGFIa from bovine EC monolayers varied considerably among strains and passage number in the same strain, results from individual experiments were expressed as the fold-increase in 6-keto-PGF1, release (Table I) . The increase in 6-keto-PGF,a was due to release from ECs and not from neutrophils, since 6-keto-PGF,a could not be detected when neutrophils were activated by PMA in the absence ofECs (<100 pg/10' neutrophils in nine experiments).
Time course and dose response ofneutrophil-mediated bovine EC 6-keto-PGF,a release. Significant 6-keto-PGFIa release was observed after a 15-min incubation of bovine EC monolayers (4) 1.1±0.7 (P > 0.05) Neutrophils (4) 1.1±0.5 (P > 0.05) Neutrophils and PMA (18) 12.2±1.5 (P < 0.001) Arachidonic acid (6) 35.1±3. with PMA-activated neutrophils (Figure 1 A) . Neutrophil-toendothelial ratios as low as 2 to 1 produced a significant increase in bovine endothelial 6-keto-PGFI. release (Figure 1 B) .
Effect ofinhibitors on neutrophil-mediated bovine endothelial 6-keto-PGFIa release. The effect of inhibitors on bovine endothelial 6-keto-PGFIa release induced by PMA-activated neutrophils is summarized in Table II Effect ofPMA-activated chronic granulomatous disease neutrophils on bovine EC 6-keto-PGF,a release. The inhibition of endothelial 6-keto-PGF,I release after the addition of catalase to PMA-activated neutrophils suggested that hydrogen peroxide or a hydrogen peroxide-derived product was a critical mediator. To assess further the role of hydrogen peroxide, we examined the effect of PMA-activated neutrophils from a patient with chronic granulomatous disease and a patient with myeloperoxidase deficiency on endothelial 6-keto-PGFI, release. Chronic granulomatous disease neutrophils, which do not generate hydrogen peroxide, failed to induce 6-keto-PGFIa release when activated by PMA (Table III) . Note that PMA-activated myeloperoxidase-deficient neutrophils, which produce hydrogen peroxide but not hypochlorous acid, induced 6-keto-PGFIa re- Effect of glucose-glucose oxidase on bovine endothelial 6-keto-PGF,a release. After the observations that endothelial 6-keto-PGFIa release required a normal neutrophil oxidative burst and was catalase inhibitable, we examined the effect of a cell-free hydrogen peroxide-generating system, glucose-glucose oxidase, on bovine endothelial 6-keto-PGFIa release. The addition ofglucose-glucose oxidase to bovine EC monolayers produced significant catalase-inhibitable 6-keto-PGFIa release (Table   IV A ). The boiling of glucose oxidase before its addition to the monolayer prevented 6-keto-PGFI, release, and the boiling of catalase abolished its inhibitory effect, indicating that for both, enzymatic activity was required (Table IV A ). Bovine EC 6- keto-PGFIa release induced by glucose-glucose oxidase was inhibited by the phospholipase inhibitor mepacrine (23) ( Table   IV B) .
Effect of hydrogen peroxide on human EC 6-keto-PGF,a release. Because the bovine EC strains employed in these studies were multiply passaged, we were concerned that the effect of hydrogen peroxide on PGI2 release might be due to some alteration in arachidonic acid metabolism that occurred with prolonged passage. It is known, for example, that the amount of 6-keto-PGFI,a released from bovine aortic and pulmonary artery ECs after stimulation with ionophore or arachidonic acid decreases markedly with passage and that there is a shift from production of PGI2 to production of other prostanoids (24, 25). For this reason, we also examined the effect ofhydrogen peroxide on first passage human umbilical vein ECs. Both PMA-activated neutrophils and glucose-glucose oxidase induced dose-dependent release of 6-keto-PGFI from human umbilical vein ECs (Fig. 2) . The amount of6-keto-PGFIa released Glucose Oxidase (mU/ml) Figure 2 . Hydrogen peroxide-mediated human umbilical vein EC 6-keto-PGFI. release. In A, human EC monolayers were incubated in Neuman-Tytell medium (22 mM glucose) with or without PMA-activated neutrophils. Catalase (3,000 U/ml) (closed triangle) was added to the neutrophils before the addition of PMA. Aliquots of cell-free supernatant medium were removed at 30 min for determination of 6-keto-PGF,I. Values represent mean± 1 SE of four replicate wells. In B, human EC monolayers were incubated in Neuman-Tytell medium with or without glucose oxidase. At 30 min aliquots of cell-free supernatant medium were removed for determination of 6-keto-PGF,. by RIA. Values represent mean±1 SE of three replicate wells. 445 Neutrophil-mediated Endothelial Prostacyclin Release I with the bovine cells. However, the levels of 6-keto-PGFIa released by A23187 or arachidonic acid were likewise five-to tenfold greater in human cells than in bovine cells (data not shown). As with bovine ECs, the release of 6-keto-PGFIa from the human ECs incubated with PMA-activated neutrophils (Fig.  2 A) and with glucose-glucose oxidase (data not shown) was inhibited by catalase.
TLC of hydrogen peroxide-mediated EC 6-keto-PGFia release. The release of 6-keto-PGF,a from ECs induced by neutrophil-derived and enzymatically generated hydrogen peroxide was confirmed by TLC. Table V A demonstrates the catalaseinhibitable release of labeled 6-keto-PGF,a, PGE2, and arachidonic acid from prelabeled human EC monolayers incubated with PMA-activated neutrophils. Table V B demonstrates the catalase-inhibitable release of these labeled products from prelabeled human EC monolayers incubated with glucose-glucose oxidase.
Relation ofhydrogen peroxide-mediated endothelial 6-ketoPGFia release to cell lysis. The rapid release of 6-keto-PGFi,a from bovine EC monolayers during incubation with PMA-activated neutrophils was not correlated with EC lysis, as determined by 5'Cr release. Specific endothelial 5"Cr release was not observed even after a 4-h incubation of 5'Cr-labeled EC monolayers with PMA-activated neutrophils (Table VI) . PMA-activated neutrophils also failed to induce significant specific 5'Cr release from human EC monolayers at 4 h (data not shown). 
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Bovine aortic EC monolayers were labeled overnight with 5'Cr, washed, and then incubated with control medium, neutrophils (neutrophil to endothelial ratio of 10 to 1), PMA (10 ng/ml), neutrophils and PMA, or Triton X-100 (0.1%). After 4 h an aliquot of cell-free supernatant medium was removed for determination of 5'Cr release. Values represent mean± 1 SE of (n) replicates.
Discussion
The acute inflammatory response is characterized by neutrophil adherence to endothelium and neutrophil accumulation at the inflammatory site (1) . The vascular response to neutrophil infiltration includes an increase in local blood flow and altered vascular permeability, resulting in edema formation. Numerous studies have implicated prostaglandins, particularly PGE2 and PGI2, as critical mediators of the hyperemia and increased permeability that accompany the neutrophil infiltration (2, (9) (10) (11) (12) (13) (14) (15) (16) . Because the vascular endothelium releases PGI2 and PGE2 when stimulated (26) , ECs are a potential source for the local production of these prostaglandins during the acute inflammatory response.
Our studies demonstrate that PMA-activated human peripheral blood neutrophils induce a time-and dose-dependent release of PGI2 from cultured ECs. Since PMA does not induce the release of arachidonic acid metabolites from human neutrophils (27) , and aspirin pretreatment of the endothelium prevented 6-keto-PGF,a release, it is unlikely that endothelial PGI2 release occurs as a result of the provision of a substrate for endothelial cyclooxygenase by neutrophil-generated endoperoxides, as has been described for platelet-endothelial interactions (28 release from ECs incubated with PMA-activated neutrophils, it appears that hydrogen peroxide or a hydrogen peroxide-derived product is the critical neutrophil-generated mediator. This is supported by the observation that the hydrogen peroxide-generating system, glucose-glucose oxidase, can also induce catalaseinhibitable PGI2 release from cultured ECs over the same time course. Catalase did not always completely inhibit neutrophilmediated PGI2 release, whereas it totally prevented glucoseglucose oxidase-mediated release; this may be due to exclusion of this enzyme at sites where neutrophils and ECs adhere closely.
Our observation that peroxide-stimulated prostaglandin generation by ECs is not associated with cellular lysis has also been recently reported by Ager and Gordon (33) . These investigators found that porcine aortic endothelium synthesized PGI2 and PGE2 in response to enzymatically generated hydrogen peroxide at a concentration significantly lower than that which was lethal to the cells.
The results obtained by TLC confirm those obtained by RIA. The TLC results demonstrate that enzymatically or neutrophil-generated hydrogen peroxide induces the release of labeled arachidonic acid, 6-keto-PGFIa, and PGE2 from prelabeled endothelial cells. Hydrogen peroxide has been observed to induce PGE2 release from fibroblasts, and an organic peroxide has been reported to induce PGI2 release from ECs (34, 35) . The inhibition of hydrogen peroxide-induced endothelial PGI2 release by the phospholipase inhibitor mepacrine (23) suggests that hydrogen peroxide may act by triggering membrane phospholipase A2, thus liberating arachidonic acid as a substrate for cyclooxygenase.
The conversion of the arachidonic acid released by the exogenously generated hydrogen peroxide to PGI2 is a cyclooxygenase-catalyzed event, since it is inhibited by aspirin. The reported effects of peroxides on the cyclooxygenase-dependent conversion are variable. Peroxides have been observed to both activate (36, 37) and inactivate cyclooxygenase (38) . Since hydroperoxides can inactivate endothelial PGI2 synthetase (39) , peroxides may also affect the subsequent conversion of the endoperoxides generated by cyclooxygenase. If cyclooxygenase is stimulated while PGI2 synthetase is inhibited, enhanced synthesis of PGE2 may occur (40) .
The effects ofexogenously generated peroxides on endothelial arachidonic acid metabolism may be critically dose dependent.
Taylor et al. noted that high concentrations of hydroperoxides inhibited 6-keto-PGF1,, production in bovine ECs and PGE2 in fibroblasts, whereas low concentrations stimulated prostaglandin release (35) . Hydrogen peroxide-induced endothelial prostaglandin production may thus be a net result of complex stimulatory and inhibitory effects on the various enzyme systems involved.
The observation that exogenously generated hydrogen peroxide can induce the release of PGI2 from cultured ECs is of particular interest in acute inflammation where the endothelium may be exposed to hydrogen peroxide generated by inflammatory cells such as neutrophils and monocytes. The release ofa potent vasodilator such as PGI2 may augment local edema formation (2, (9) (10) (11) (12) (13) (14) (15) (16) . Alternatively, the release of PGI2 could prevent the adherence and activation of additional inflammatory cells by elevating intracellular cyclic AMP (41) (42) (43) (44) . The demonstration that a toxic oxygen radical generated by one cell can trigger the release of arachidonic acid metabolites by another cell further illustrates the possibilities for interactions between inflammatory mediators.
